Artículos de revistas: "Host-directed"

1

Wilkinson, Robert John. "Host-directed therapies against tuberculosis". Lancet Respiratory Medicine 2, n.º 2 (febrero de 2014): 85–87. http://dx.doi.org/10.1016/s2213-2600(13)70295-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Stricker, Raphael B. "Host-Directed Therapy for AIDS". Annals of Internal Medicine 123, n.º 6 (15 de septiembre de 1995): 471. http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00019.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Lederman, Michael M. "Host-Directed Therapy for AIDS". Annals of Internal Medicine 123, n.º 6 (15 de septiembre de 1995): 472. http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00020.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Jeong, Eui-Kwon, Hyo-Ji Lee y Yu-Jin Jung. "Host-Directed Therapies for Tuberculosis". Pathogens 11, n.º 11 (3 de noviembre de 2022): 1291. http://dx.doi.org/10.3390/pathogens11111291.

Texto completo

Resumen

Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-resistant TB; therefore, the development of new TB treatment strategies is urgently needed. In this context, we present host-directed therapy (HDT) as an alternative to current tuberculosis therapy. Unlike antitubercular drugs that directly target Mycobacterium tuberculosis (Mtb), the causative agent of TB, HDT is an approach for treating TB that appropriately modulates host immune responses. HDT primarily aims to enhance the antimicrobial activity of the host in order to control Mtb infection and attenuate excessive inflammation in order to minimize tissue damage. Recently, research based on the repositioning of drugs for use in HDT has been in progress. Based on the overall immune responses against Mtb infection and the immune-evasion mechanisms of Mtb, this review examines the repositioned drugs available for HDT and their mechanisms of action.

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Maeurer, Markus, Renata Ramalho, Fu-Sheng Wang y Alimuddin Zumla. "Host-directed therapies for COVID-19". Current Opinion in Pulmonary Medicine 27, n.º 3 (2 de febrero de 2021): 205–9. http://dx.doi.org/10.1097/mcp.0000000000000769.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Davis, Angharad G., Joseph Donovan, Marise Bremer, Ronald Van Toorn, Johan Schoeman, Ariba Dadabhoy, Rachel P. J. Lai et al. "Host Directed Therapies for Tuberculous Meningitis". Wellcome Open Research 5 (1 de julio de 2021): 292. http://dx.doi.org/10.12688/wellcomeopenres.16474.2.

Texto completo

Resumen

A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Singh, Bhawana, Sanjay Varikuti, Gregory Halsey, Greta Volpedo, Omar M. Hamza y Abhay R. Satoskar. "Host-directed therapies for parasitic diseases". Future Medicinal Chemistry 11, n.º 15 (agosto de 2019): 1999–2018. http://dx.doi.org/10.4155/fmc-2018-0439.

Texto completo

Resumen

Parasitic infections are responsible for significant morbidity and mortality throughout the world. Management strategies rely primarily on antiparasitic drugs that have side effects and risk of drug resistance. Therefore, novel strategies are needed for treatment of parasitic infections. Host-directed therapy (HDT) is a viable alternative, which targets host pathways responsible for parasite invasion/survival/pathogenicity. Recent innovative combinations of genomics, proteomics and computational biology approaches have led to discovery of several host pathways that could be promising targets for HDT for treating parasitic infections. Herein, we review major advances in HDT for parasitic disease with regard to core regulatory pathways and their interactions.

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Davis, Angharad G., Joseph Donovan, Marise Bremer, Ronald Van Toorn, Johan Schoeman, Ariba Dadabhoy, Rachel PJ Lai et al. "Host Directed Therapies for Tuberculous Meningitis". Wellcome Open Research 5 (23 de diciembre de 2020): 292. http://dx.doi.org/10.12688/wellcomeopenres.16474.1.

Texto completo

Resumen

A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Guler, Reto y Frank Brombacher. "Host-directed drug therapy for tuberculosis". Nature Chemical Biology 11, n.º 10 (17 de septiembre de 2015): 748–51. http://dx.doi.org/10.1038/nchembio.1917.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Zumla, Alimuddin, Jeremiah Chakaya, Michael Hoelscher, Francine Ntoumi, Roxana Rustomjee, Cristina Vilaplana, Dorothy Yeboah-Manu et al. "Towards host-directed therapies for tuberculosis". Nature Reviews Drug Discovery 14, n.º 8 (17 de julio de 2015): 511–12. http://dx.doi.org/10.1038/nrd4696.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Zumla, A., M. Rao, S. K. Parida, S. Keshavjee, G. Cassell, R. Wallis, R. Axelsson-Robertsson, M. Doherty, J. Andersson y M. Maeurer. "Inflammation and tuberculosis: host-directed therapies". Journal of Internal Medicine 277, n.º 4 (19 de mayo de 2014): 373–87. http://dx.doi.org/10.1111/joim.12256.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Rao, Martin, Alimuddin Zumla y Markus Maeurer. "Host-directed therapy: tuberculosis vaccine development". Lancet Respiratory Medicine 3, n.º 3 (marzo de 2015): 172–73. http://dx.doi.org/10.1016/s2213-2600(15)00055-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Wallis, Robert S. y Richard Hafner. "Advancing host-directed therapy for tuberculosis". Nature Reviews Immunology 15, n.º 4 (13 de marzo de 2015): 255–63. http://dx.doi.org/10.1038/nri3813.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Zumla, Alimuddin, Markus Maeurer, Guido Moll y Bongani M. Mayosi. "Host-directed therapies for tuberculous pericarditis". International Journal of Infectious Diseases 32 (marzo de 2015): 30–31. http://dx.doi.org/10.1016/j.ijid.2014.11.017.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Gomes, Maria Salomé y Luisa Pereira. "Special Issue: From Host–Pathogen Interaction to Host-Directed Therapies". Microorganisms 9, n.º 12 (17 de diciembre de 2021): 2606. http://dx.doi.org/10.3390/microorganisms9122606.

Texto completo

Resumen

Despite the enormous progress made in the last few decades, infectious diseases still represent a huge challenge to human society and health systems, as evidenced by the recent SARS-CoV-2 pandemic [...]

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Hawn, T. R., A. I. Matheson, S. N. Maley y O. Vandal. "Host-Directed Therapeutics for Tuberculosis: Can We Harness the Host?" Microbiology and Molecular Biology Reviews 77, n.º 4 (1 de diciembre de 2013): 608–27. http://dx.doi.org/10.1128/mmbr.00032-13.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Kilinç, Gül, Anno Saris, Tom H. M. Ottenhoff y Mariëlle C. Haks. "Host‐directed therapy to combat mycobacterial infections*". Immunological Reviews 301, n.º 1 (9 de febrero de 2021): 62–83. http://dx.doi.org/10.1111/imr.12951.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

van Tol, Sarah, Adam Hage y Ricardo Rajsbaum. "Lighting the way to host-directed immunotherapeutics". Cell Chemical Biology 29, n.º 7 (julio de 2022): 1067–70. http://dx.doi.org/10.1016/j.chembiol.2022.06.009.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Schloer, Sebastian, Jonas Goretzko y Ursula Rescher. "Repurposing Antifungals for Host-Directed Antiviral Therapy?" Pharmaceuticals 15, n.º 2 (10 de febrero de 2022): 212. http://dx.doi.org/10.3390/ph15020212.

Texto completo

Resumen

Because of their epidemic and pandemic potential, emerging viruses are a major threat to global healthcare systems. While vaccination is in general a straightforward approach to prevent viral infections, immunization can also cause escape mutants that hide from immune cell and antibody detection. Thus, other approaches than immunization are critical for the management and control of viral infections. Viruses are prone to mutations leading to the rapid emergence of resistant strains upon treatment with direct antivirals. In contrast to the direct interference with pathogen components, host-directed therapies aim to target host factors that are essential for the pathogenic replication cycle or to improve the host defense mechanisms, thus circumventing resistance. These relatively new approaches are often based on the repurposing of drugs which are already licensed for the treatment of other unrelated diseases. Here, we summarize what is known about the mechanisms and modes of action for a potential use of antifungals as repurposed host-directed anti-infectives for the therapeutic intervention to control viral infections.

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Tobin, David M. "Host-Directed Therapies for Tuberculosis: Figure 1." Cold Spring Harbor Perspectives in Medicine 5, n.º 10 (18 de mayo de 2015): a021196. http://dx.doi.org/10.1101/cshperspect.a021196.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Zumla, Alimuddin y Markus Maeurer. "Host-directed therapies for multidrug resistant tuberculosis". International Journal of Mycobacteriology 5 (diciembre de 2016): S21—S22. http://dx.doi.org/10.1016/j.ijmyco.2016.09.044.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Pourmir, Azadeh y Tyler W. Johannes. "DIRECTED EVOLUTION: SELECTION OF THE HOST ORGANISM". Computational and Structural Biotechnology Journal 2, n.º 3 (septiembre de 2012): e201209012. http://dx.doi.org/10.5936/csbj.201209012.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Szychowski, J. A., G. Vidalakis y J. S. Semancik. "Host-directed processing of Citrus exocortis viroid". Journal of General Virology 86, n.º 2 (1 de febrero de 2005): 473–77. http://dx.doi.org/10.1099/vir.0.80699-0.

Texto completo

Resumen

Prolonged infection of tomato hybrid (Lycopersicon esculentum×Lycopersicon peruvianum) by Citrus exocortis viroid (CEVd) resulted in viroid-like enlarged structures, detected by gel electrophoresis. This population included two new enlarged variants or D-variants, D-87 and D-76, and three transient species or D-forms, D-38, D-40 and D-43. Sequence analyses exposed a locus near the terminal repeat region where major changes appeared consistently. In transmission tests to CEVd hosts, a variety of progeny populations were recovered, including progeny enlargements of and reversions to CEVd, as well as sequence fidelity to the inoculum. Transmission tests to citrus hosts of the genera Citrus, Poncirus or Fortunella were unsuccessful. The importance of host specificity to the recovery and processing of the various CEVd-related structures, as well as the temporal variability of progeny populations, was demonstrated.

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Cholewa, Piotr P., Christine M. Beavers, Simon J. Teat y Scott J. Dalgarno. "Directed assembly via selectively positioned host functionality". Chemical Communications 49, n.º 31 (2013): 3203. http://dx.doi.org/10.1039/c3cc40564h.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Moore, Terry W., Kasinath Sana, Dan Yan, Pahk Thepchatri, John M. Ndungu, Manohar T. Saindane, Mark A. Lockwood et al. "Asymmetric synthesis of host-directed inhibitors of myxoviruses". Beilstein Journal of Organic Chemistry 9 (30 de enero de 2013): 197–203. http://dx.doi.org/10.3762/bjoc.9.23.

Texto completo

Resumen

High-throughput screening (HTS) previously identified benzimidazole 1 (JMN3-003) as a compound with broad antiviral activity against different influenza viruses and paramyxovirus strains. In pursuit of a lead compound from this series for development, we sought to increase both the potency and the aqueous solubility of 1. Lead optimization has achieved compounds with potent antiviral activity against a panel of myxovirus family members (EC50 values in the low nanomolar range) and much improved aqueous solubilities relative to that of 1. Additionally, we have devised a robust synthetic strategy for preparing 1 and congeners in an enantio-enriched fashion, which has allowed us to demonstrate that the (S)-enantiomers are generally 7- to 110-fold more potent than the corresponding (R)-isomers.

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Gina, P., M. Davids y K. Dheda. "Manipulation of autophagy for host-directed tuberculosis therapy". African Journal of Thoracic and Critical Care Medicine 25, n.º 2 (31 de julio de 2019): 49. http://dx.doi.org/10.7196/sarj.2019.v25i2.014.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

DiNardo, Andrew R., Tomoki Nishiguchi, Sandra L. Grimm, Larry S. Schlesinger, Edward A. Graviss, Jeffrey D. Cirillo, Cristian Coarfa et al. "Tuberculosis endotypes to guide stratified host-directed therapy". Med 2, n.º 3 (marzo de 2021): 217–32. http://dx.doi.org/10.1016/j.medj.2020.11.003.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Dara, Yash, Doron Volcani, Kush Shah, Kevin Shin y Vishwanath Venketaraman. "Potentials of Host-Directed Therapies in Tuberculosis Management". Journal of Clinical Medicine 8, n.º 8 (3 de agosto de 2019): 1166. http://dx.doi.org/10.3390/jcm8081166.

Texto completo

Resumen

Tuberculosis (TB) remains as a leading cause of mortality in developing countries, persisting as a major threat to the global public health. Current treatment involving a long antibiotic regimen brings concern to the topic of patient compliance, contributing to the emergence of drug resistant TB. The current review will provide an updated outlook on novel anti-TB therapies that can be given as adjunctive agents to current anti-TB treatments, with a particular focus on modulating the host immune response to effectively target all forms of TB. Additional potential therapeutic pathway targets, including lipid metabolism alteration and vascular endothelial growth factor (VEGF)-directed therapies, are discussed.

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Zumla, Alimuddin, Giuseppe Ippolito, Francine Ntoumi, Vicki Seyfert-Margolies, Tumaini J. Nagu, Daniela Cirillo, Jeremiah Muhwa Chakaya, Ben Marais y Markus Maeurer. "Host-directed therapies and holistic care for tuberculosis". Lancet Respiratory Medicine 8, n.º 4 (abril de 2020): 337–40. http://dx.doi.org/10.1016/s2213-2600(20)30078-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Zeng, Qiang, Reena Marthi, Andrea McNally, Calum Dickinson, Tia E. Keyes y Robert J. Forster. "Host−Guest Directed Assembly of Gold Nanoparticle Arrays". Langmuir 26, n.º 2 (19 de enero de 2010): 1325–33. http://dx.doi.org/10.1021/la902258s.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Kaufmann, Stefan H. E., Anca Dorhoi, Richard S. Hotchkiss y Ralf Bartenschlager. "Host-directed therapies for bacterial and viral infections". Nature Reviews Drug Discovery 17, n.º 1 (22 de septiembre de 2017): 35–56. http://dx.doi.org/10.1038/nrd.2017.162.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Radke, Jay R., C. Amy Eibs y Philip D. Fox. "Host Cell-Directed Interactions with Toxoplasma Influence Pathogenesis". Microbe Magazine 2, n.º 5 (1 de mayo de 2007): 244–50. http://dx.doi.org/10.1128/microbe.2.244.1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Khitrov, Gregory. "Host-Directed Polar Order Observed in Organic Molecular Crystals". MRS Bulletin 25, n.º 8 (agosto de 2000): 5–6. http://dx.doi.org/10.1557/mrs2000.138.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Mehta, Krina, Herman P. Spaink, Tom H. M. Ottenhoff, Piet H. van der Graaf y J. G. Coen van Hasselt. "Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches". Trends in Pharmacological Sciences 43, n.º 4 (abril de 2022): 293–304. http://dx.doi.org/10.1016/j.tips.2021.11.016.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

Wei, Ling, Jack Adderley, Didier Leroy, David H. Drewry, Danny W. Wilson, Alexis Kaushansky y Christian Doerig. "Host-directed therapy, an untapped opportunity for antimalarial intervention". Cell Reports Medicine 2, n.º 10 (octubre de 2021): 100423. http://dx.doi.org/10.1016/j.xcrm.2021.100423.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Sachan, Madhur, Ashish Srivastava, Rajeev Ranjan, Anuradha Gupta, Sanketkumar Pandya y Amit Misra. "Opportunities and Challenges for Host-Directed Therapies in Tuberculosis". Current Pharmaceutical Design 22, n.º 17 (27 de abril de 2016): 2599–604. http://dx.doi.org/10.2174/1381612822666160128150636.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Barber, Ron. "Host-directed short-term missions: Interviews with Japanese liaisons". Missiology: An International Review 43, n.º 3 (21 de abril de 2015): 309–23. http://dx.doi.org/10.1177/0091829615581930.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

Maeurer, Markus, Martin Rao y Alimuddin Zumla. "Host-directed therapies for antimicrobial resistant respiratory tract infections". Current Opinion in Pulmonary Medicine 22, n.º 3 (mayo de 2016): 203–11. http://dx.doi.org/10.1097/mcp.0000000000000271.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Young, C., G. Walzl y N. Du Plessis. "Therapeutic host-directed strategies to improve outcome in tuberculosis". Mucosal Immunology 13, n.º 2 (26 de noviembre de 2019): 190–204. http://dx.doi.org/10.1038/s41385-019-0226-5.

Texto completo

Resumen

AbstractBacille Calmette-Guérin (BCG) is the only licenced tuberculosis (TB) vaccine, but has limited efficacy against pulmonary TB disease development and modest protection against extrapulmonary TB. Preventative antibiotic treatment for Mycobacterium tuberculosis (Mtb) infections in high-prevalence settings is unfeasible due to unclear treatment durability, drug toxicity, logistical constraints related to directly observed treatment strategy (DOTS) and the lengthy treatment protocols. Together, these factors promote non-adherence, contributing to relapse and establishment of drug-resistant Mtb strains. Although antibiotic treatment of drug-susceptible Mtb is generally effective, drug-resistant TB has a treatment efficacy below 50% and can, in a proportion, develop into progressive, untreatable disease. Other immune compromising co-infections and/or co-morbidities require more complex prevention/treatment approaches, posing huge financial burdens to national health services. Novel TB treatment strategies, such as host-directed therapeutics, are required to complement pathogen-targeted approaches. Pre-clinical studies have highlighted promising candidates that enhance endogenous pathways and/or limit destructive host responses. This review discusses promising pre-clinical candidates and forerunning compounds at advanced stages of clinical investigation in TB host-directed therapeutic (HDT) efficacy trials. Such approaches are rationalized to improve outcome in TB and shorten treatment strategies.

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

O'Brien, Philippa M. y M. Saveria Campo. "Evasion of host immunity directed by papillomavirus-encoded proteins". Virus Research 88, n.º 1-2 (septiembre de 2002): 103–17. http://dx.doi.org/10.1016/s0168-1702(02)00123-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Dallenga, Tobias, Lara Linnemann, Bhesh Paudyal, Urska Repnik, Gareth Griffiths y Ulrich E. Schaible. "Targeting neutrophils for host-directed therapy to treat tuberculosis". International Journal of Medical Microbiology 308, n.º 1 (enero de 2018): 142–47. http://dx.doi.org/10.1016/j.ijmm.2017.10.001.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

Schwegmann, A. y F. Brombacher. "Host-Directed Drug Targeting of Factors Hijacked by Pathogens". Science Signaling 1, n.º 29 (15 de julio de 2008): re8. http://dx.doi.org/10.1126/scisignal.129re8.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Bull, James J., Holly A. Wichman y Stephen M. Krone. "Modeling the Directed Evolution of Broad Host Range Phages". Antibiotics 11, n.º 12 (27 de noviembre de 2022): 1709. http://dx.doi.org/10.3390/antibiotics11121709.

Texto completo

Resumen

Background: The host ranges of individual phages tend to be narrow, yet many applications of phages would benefit from expanded host ranges. Empirical methods have been developed to direct the evolution of phages to attack new strains, but the methods have not been evaluated or compared for their consequences. In particular, how do different methods favor generalist (broad host range) phages over specialist phages? All methods involve exposing phages to two or more novel bacterial strains, but the methods differ in the order in which those hosts are presented through time: Parallel presentation, Sequential presentation, and Mixed presentation. Methods: We use a combination of simple analytical methods and numerical analyses to study the effect of these different protocols on the selection of generalist versus specialist phages. Results: The three presentation protocols have profoundly different consequences for the evolution of generalist versus specialist phages. Sequential presentation favors generalists almost to the exclusion of specialists, whereas Parallel presentation does the least so. However, other protocol attributes (the nature of dilution between transfers of phages to new cultures) also have effects on selection and phage maintenance. It is also noted that protocols can be designed to enhance recombination to augment evolution and to reduce stochastic loss of newly arisen mutants.

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Wale, Nina, Matthew J. Jones, Derek G. Sim, Andrew F. Read y Aaron A. King. "The contribution of host cell-directed vs. parasite-directed immunity to the disease and dynamics of malaria infections". Proceedings of the National Academy of Sciences 116, n.º 44 (15 de octubre de 2019): 22386–92. http://dx.doi.org/10.1073/pnas.1908147116.

Texto completo

Resumen

Hosts defend themselves against pathogens by mounting an immune response. Fully understanding the immune response as a driver of host disease and pathogen evolution requires a quantitative account of its impact on parasite population dynamics. Here, we use a data-driven modeling approach to quantify the birth and death processes underlying the dynamics of infections of the rodent malaria parasite, Plasmodium chabaudi, and the red blood cells (RBCs) it targets. We decompose the immune response into 3 components, each with a distinct effect on parasite and RBC vital rates, and quantify the relative contribution of each component to host disease and parasite density. Our analysis suggests that these components are deployed in a coordinated fashion to realize distinct resource-directed defense strategies that complement the killing of parasitized cells. Early in the infection, the host deploys a strategy reminiscent of siege and scorched-earth tactics, in which it both destroys RBCs and restricts their supply. Late in the infection, a “juvenilization” strategy, in which turnover of RBCs is accelerated, allows the host to recover from anemia while holding parasite proliferation at bay. By quantifying the impact of immunity on both parasite fitness and host disease, we reveal that phenomena often interpreted as immunopathology may in fact be beneficial to the host. Finally, we show that, across mice, the components of the host response are consistently related to each other, even when infections take qualitatively different trajectories. This suggests the existence of simple rules that govern the immune system’s deployment.

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Ahmed, Sultan, Rubhana Raqib, Guðmundur Hrafn Guðmundsson, Peter Bergman, Birgitta Agerberth y Rokeya Sultana Rekha. "Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation". Antibiotics 9, n.º 1 (7 de enero de 2020): 21. http://dx.doi.org/10.3390/antibiotics9010021.

Texto completo

Resumen

Tuberculosis (TB) is one of the leading causes of mortality and morbidity, particularly in developing countries, presenting a major threat to the public health. The currently recommended long term treatment regimen with multiple antibiotics is associated with poor patient compliance, which in turn, may contribute to the emergence of multi-drug resistant TB (MDR-TB). The low global treatment efficacy of MDR-TB has highlighted the necessity to develop novel treatment options. Host-directed therapy (HDT) together with current standard anti-TB treatments, has gained considerable interest, as HDT targets novel host immune mechanisms. These immune mechanisms would otherwise bypass the antibiotic bactericidal targets to kill Mycobacterium tuberculosis (Mtb), which may be mutated to cause antibiotic resistance. Additionally, host-directed therapies against TB have been shown to be associated with reduced lung pathology and improved disease outcome, most likely via the modulation of host immune responses. This review will provide an update of host-directed therapies and their mechanism(s) of action against Mycobacterium tuberculosis.

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Saini, Sapna, Anjali Gangwar y Rashmi Sharma. "Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis". Microbiological Research 275 (octubre de 2023): 127466. http://dx.doi.org/10.1016/j.micres.2023.127466.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Kim, Ye-Ram y Chul-Su Yang. "Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment". Journal of Microbiology and Biotechnology 27, n.º 9 (28 de septiembre de 2017): 1549–58. http://dx.doi.org/10.4014/jmb.1705.05032.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Ignatius, Elisa H. y Kelly E. Dooley. "A leap forward in assessing host-directed therapies for tuberculosis". Lancet Respiratory Medicine 9, n.º 8 (agosto de 2021): 809–10. http://dx.doi.org/10.1016/s2213-2600(20)30528-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Prussia, Andrew, Pahk Thepchatri, James P. Snyder y Richard Plemper. "Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics". International Journal of Molecular Sciences 12, n.º 6 (15 de junio de 2011): 4027–52. http://dx.doi.org/10.3390/ijms12064027.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Collier, Michael A., Matthew D. Gallovic, Kevin J. Peine, Anthony D. Duong, Eric M. Bachelder, John S. Gunn, Larry S. Schlesinger y Kristy M. Ainslie. "Delivery of host cell-directed therapeutics for intracellular pathogen clearance". Expert Review of Anti-infective Therapy 11, n.º 11 (noviembre de 2013): 1225–35. http://dx.doi.org/10.1586/14787210.2013.845524.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Artículos de revistas sobre el tema "Host-directed"

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros